Description: Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Home Page: www.resverlogix.com
RVX Technical Analysis
4820 Richard Road SW
Calgary,
AB
T3E 6L1
Canada
Phone:
403 254 9252
Officers
| Name | Title |
|---|---|
| Mr. Donald J. McCaffrey | Co-Founder, Chairman, Pres, CEO & Sec. |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | Chief Financial Officer |
| Dr. Ewelina Kulikowski Ph.D. | Chief Scientific Officer |
| Dr. Jan O. Johansson M.D., Ph.D. | Sr. VP of Medical Affairs |
| Dr. Michael Sweeney M.D. | Sr. VP of Clinical Devel. |
| Sarah Zapotichny | Director of Investor Relations & Corp. Communications |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 22 |